Table 2.

Agreement with statements regarding impact of NTM-LD on morbidity and mortality

Countries	Strongly agree	Agree	Unsure	Disagree	Strongly disagree
‘NTM-LD significantly increases morbidity and leads to more frequent hospitalisations’*
UK	12	73	12	3	0
Germany	25	58	15	2	0
Italy	13	67	10	10	0
France	22	70	8	0	0
The Netherlands	13	65	20	3	0
Mean percentage	17	67	13	4	0
‘NTM-LD has no significant impact on mortality risk, as mortality is determined by the underlying condition’
UK	3	10	23	55	8
Germany	0	7	18	53	22
Italy	0	13	32	43	12
France	2	20	28	32	18
The Netherlands	3	10	25	53	10
Mean percentage	1	12	25	47	14

The percentage of physicians choosing an answer is shown. n=280.

*Agreement with this statement weakly correlated with perceived risk of NTM in patients with bronchiectasis (Spearman’s r 0.185, p<0.01) and number of patients with NTM managed (Spearman’s r 0.174, p<0.01).

NTM-LD, non-tuberculous mycobacterial lung disease.